Next generation diagnostics: rete transfrontaliera per lo sviluppo e il trasferimento di metodologie molecolari nella medicina di precisione oncologica
ProjectThe project addresses, in an integrated and cross-border manner, one of the main challenges faced
by the territory between Lombardy and the Canton of Ticino: the rising incidence of highly aggressive
tumors and the shortage of tools and skills for early and personalized diagnosis. While oncology is
increasingly shifting towards predictive and personalized models, access to precision medicine
remains limited due to fragmented expertise, poor interoperability between clinical facilities and
research centers, and a lack of specialized personnel.
The intervention area is characterized by a high concentration of scientific and clinical expertise, yet
still faces structural barriers. Among the shared challenges are:
• fragmented funding and a less competitive innovation ecosystem compared to other
international contexts;
• limited interaction between research centers and companies, hindering effective technology
transfer;
• a weak entrepreneurial culture in academia;
• difficulties for companies in developing internal innovation skills, highlighting the need for
interdisciplinary collaborative models.
In oncology, early and molecular diagnosis is a common priority: anticipating a tumor’s response to
therapy means improving clinical outcomes, reducing costs, and optimizing healthcare resources.
Despite the clear medical need and the market interest, these goals are currently hampered by a
shortage of trained personnel and the absence of shared diagnostic platforms.
by the territory between Lombardy and the Canton of Ticino: the rising incidence of highly aggressive
tumors and the shortage of tools and skills for early and personalized diagnosis. While oncology is
increasingly shifting towards predictive and personalized models, access to precision medicine
remains limited due to fragmented expertise, poor interoperability between clinical facilities and
research centers, and a lack of specialized personnel.
The intervention area is characterized by a high concentration of scientific and clinical expertise, yet
still faces structural barriers. Among the shared challenges are:
• fragmented funding and a less competitive innovation ecosystem compared to other
international contexts;
• limited interaction between research centers and companies, hindering effective technology
transfer;
• a weak entrepreneurial culture in academia;
• difficulties for companies in developing internal innovation skills, highlighting the need for
interdisciplinary collaborative models.
In oncology, early and molecular diagnosis is a common priority: anticipating a tumor’s response to
therapy means improving clinical outcomes, reducing costs, and optimizing healthcare resources.
Despite the clear medical need and the market interest, these goals are currently hampered by a
shortage of trained personnel and the absence of shared diagnostic platforms.